Establishment of patient-derived 3D tumouroids: Personalised medicine tools for renal cancer
Acta Biomaterialia · 2026-03 · 212 · 373-382
DOI: 10.1016/j.actbio.2025.12.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-03. Verfasst von Kalliopi Bokea und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgery and Interventional Science, University College London, London, United Kingdom. Electronic address: kalliopi.bokea.19@ucl.ac.uk. Hauptthemen laut MEDLINE: Kidney Neoplasms, Precision Medicine, Carcinoma, Renal Cell, Spheroids, Cellular. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Cancer Research Foundation, Royal Free Charity.
Abstract (Originalsprache)
Despite therapeutic advancements in the management of Renal Cell Carcinoma (RCC), there is an unmet clinical need for patient-specific in vitro models that can predict responses to therapy and enhance our understanding of this heterogeneous disease. Here, we established biomimetic 3D in vitro models, termed tumouroids, that incorporate patient-derived tumour cells and a complex stroma to mimic the physiological tumour microenvironment. We isolated tumour cells from RCC surgical specimens (n = 20) using a mechanical-enzymatic method. Two tumouroid types were manufactured: simple tumouroids consisting of patient-derived tumour cells, collagen and matrix proteins, and complex tumouroids that incorporated an additional stromal compartment populated with fibroblasts and endothelial cells. An important feature of tumouroids is that owing to fabrication via plastic compression their density mimics in vivo physiological tissue density. Patient-derived cells and tumouroids were characterised through immunofluorescence and histology to investigate resemblance to original tissues. Finally, tumouroids were subjected to treatment with Pazopanib (Votrient™), a tyrosine kinase inhibitor (TKI) used in the treatment of advanced RCC. Patient-derived tumouroids maintained the expression of characteristic RCC protein markers: carbonic anydrase IX (CA9), cytokeratins (CK7, CK8&18) and EMT markers (αSMA). The subtype-specific histology of the original tumour, e.g., clear cell, was also preserved. We observed Pazopanib-induced cytotoxicity, as measured by ATP production, ranging from none to strong (40 %) for individual patient-derived simple tumouroids (n = 12). In complex tumouroids, endothelial networks were also disrupted. Overall, patient-derived tumouroids mimicked the original tissue and successfully reproduced the response signatures to TKIs. STATEMENT OF SIGNIFICANCE: A significant number of renal cell carcinoma patients do not respond to targeted therapies or develop resistance and succumb to the disease. Here, we developed sophisticated 3D in vitro tumour models, termed tumouroids, from patient samples. Tumouroids mimic the original tumour and its microenvironment and elicit response to drugs that target both the tumour cells and the tumour microenvironment. This is a patient-specific in vitro tool that addresses the unmet clinical need for predicting an individual's response to therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgery and Interventional Science, University College London, London, United Kingdom. Electronic address: kalliopi.bokea.19@ucl.ac.uk.
- Division of Surgery and Interventional Science, University College London, London, United Kingdom.
- Division of Surgery and Interventional Science, University College London, London, United Kingdom; Medical School, University College London, United Kingdom.
- Division of Surgery and Interventional Science, University College London, London, United Kingdom; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, , United Arab Emirates.
- Division of Surgery and Interventional Science, University College London, London, United Kingdom; The Specialist Centre for Kidney Cancer, Royal Free Hospital, London, United Kingdom.
- Centre for 3D Models of Health and Disease, Division of Surgery and Interventional Science, University College London, London, United Kingdom.
Förderung
- Cancer Research Foundation
- Royal Free Charity
Zitieren
APA
Bokea, K., Azimi, T., Stamati, K., Braithwaite, W., Abdal, E., Hamoudi, R., Mumtaz, F., Yaghini, E., MacRobert, A. J., Cheema, U., Tran, M. G., & Loizidou, M. (2026). Establishment of patient-derived 3D tumouroids: Personalised medicine tools for renal cancer. Acta Biomaterialia, 212, 373-382. https://doi.org/10.1016/j.actbio.2025.12.033
Vancouver
Bokea K, Azimi T, Stamati K, Braithwaite W, Abdal E, Hamoudi R, et al. Establishment of patient-derived 3D tumouroids: Personalised medicine tools for renal cancer. Acta Biomaterialia. 2026;212:373-382. doi:10.1016/j.actbio.2025.12.033
BibTeX
@article{Bokea2026,
author = {Bokea, Kalliopi and Azimi, Tayebeh and Stamati, Katerina and Braithwaite, William and Abdal, Ebrahim and Hamoudi, Rifat and Mumtaz, Faiz and Yaghini, Elnaz and MacRobert, Alexander J and Cheema, Umber and Tran, Maxine Gb and Loizidou, Marilena},
title = {Establishment of patient-derived 3D tumouroids: Personalised medicine tools for renal cancer},
journal = {Acta Biomaterialia},
year = {2026},
volume = {212},
pages = {373--382},
doi = {10.1016/j.actbio.2025.12.033}
}
EUVIMED